IL6 and chronic obstructive pulmonary disease: The magnitude of the reduction in IL-6 and CXCL8 concentration was significant in patients with COPD treated with simvastatin compared with subjects treated with placebo (mean difference, −45.3 pg/mL [95% CI, −71.3 to −19.4 pg/mL], P = .002; −190.9 pg/mL (95% CI, −324.1 to −57.7), P = .007, respectively) (Figs 4A, 4B, Table 3).